United States set
language
Menu Shopping cart $0 Search
Manufactured by BioVendor

Bcl-2 Human ELISA

  • Regulatory status:RUO
  • Type:Sandwich ELISA, Biotin-labelled antibody
  • Other names:Apoptosis regulator Bcl 2
  • Species:Human
Cat. No. Size Price


RAF005R 96 wells (1 kit) $721,83
PubMed Product Details
Technical Data

Type

Sandwich ELISA, Biotin-labelled antibody

Applications

Serum, Plasma, Cell culture lysate

Sample Requirements

20 µl/well

Shipping

At ambient temperature. Upon receipt, store the product at the temperature recommended below.

Storage/Expiration

Store the complete kit at 2–8°C. Under these conditions, the kit is stable until the expiration date (see label on the box).

Calibration Curve

Calibration Range

0.5–32 ng/ml

Limit of Detection

0.5 ng/ml

Intra-assay (Within-Run)

CV = 8.6%

Inter-assay (Run-to-Run)

CV = 12.0%

Spiking Recovery

71,00%

Dilution Linearity

102,00%

Summary

Research topic

Apoptosis

Summary

Bcl-2 initiates a new gene family involved in the regulation of cell death and survival without affecting cell proliferation. This precise regulation and maintenance of balance between cell proliferation and cell death in multicellular organisms is critical for tissue homeostasis. Bcl-2, encoded by a proto-oncogene, is an intracellular membrane-associated protein that functions to block programmed cell death. Expression of Bcl-2 has been reported in a wide range of hematopoietic cells, nonneoplastic epithelia and epithelial malignancies. Bcl-2 levels are low or undetectable in endothelial cells.
The Bcl-2 gene has a unique function among mammalian oncogenes as a negative regulator of apoptosis. It was first discovered because of its involvement in chromosomal translocations commonly found in lymphomas. Bcl-2 is furthermore associated with stem cells committed to differentiation and morphogenesis.
A decrease in Bcl-2 levels leads to cell death by apoptosis. Overexpression of Bcl-2 on the other hand protects cells from death, but it is neither able to immortalize normal cells, nor to cause tumorgenic transformation of immortalized cells.
Heterogeneous expression of Bcl-2 in malignancies suggests that the gene is differentially regulated. Furthermore, its expression in association with precancerous lesions suggests a role in the early stage of tumorigenesis.
Several homologs of Bcl-2 have recently been discovered, some of which function as inhibitors of cell death and others as promoters of apoptosis that oppose the function of the Bcl-2 protein. Bcl-2 protein plays a critical role in oncogenesis as well as resistance to therapy of cancer. Furthermore prognostic significance of Bcl-2 expression has been shown for several malignancies such as Non-Hodgkin’s Lymphoma, squamous cell carcinomas, breast carcinoma, carcinoma of the gallbladder, and thymoma. Dysregulated Bcl-2 expression has
been shown in Multiple Myeloma patients and in acute Myeloid leukemia. Bcl-2 has been suggested as a useful marker for adequate IL-2 therapy e.g. in AIDS patients.

Summary References (12)

References to Bcl-2

  • Barbareschi M, Caffo O, Veronese S, Leek RD, Fina P, Fox S, Bonzanini M, Girlando S, Morelli L, Eccher C, Pezzella F, Doglioni C, Dalla Palma P, Harris A. Bcl-2 and p53 expression in node-negative breast carcinoma: a study with long-term follow-up. Hum Pathol. 1996 Nov;27 (11):1149-55
  • Chen FF, Yan JJ, Jin YT, Su IJ. Detection of bcl-2 and p53 in thymoma: expression of bcl-2 as a reliable marker of tumor aggressiveness. Hum Pathol. 1996 Oct;27 (10):1089-92
  • Hill ME, MacLennan KA, Cunningham DC, Vaughan Hudson B, Burke M, Clarke P, Di Stefano F, Anderson L, Vaughan Hudson G, Mason D, Selby P, Linch DC. Prognostic significance of BCL-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma: a British National Lymphoma Investigation Study. Blood. 1996 Aug 1;88 (3):1046-51
  • Karsan A, Yee E, Kaushansky K, Harlan JM. Cloning of human Bcl-2 homologue: inflammatory cytokines induce human A1 in cultured endothelial cells. Blood. 1996 Apr 15;87 (8):3089-96
  • Lisovsky M, Estrov Z, Zhang X, Consoli U, Sanchez-Williams G, Snell V, Munker R, Goodacre A, Savchenko V, Andreeff M. Flt3 ligand stimulates proliferation and inhibits apoptosis of acute myeloid leukemia cells: regulation of Bcl-2 and Bax. Blood. 1996 Nov 15;88 (10):3987-97
  • Lu QL, Abel P, Foster CS, Lalani EN. bcl-2: role in epithelial differentiation and oncogenesis. Hum Pathol. 1996 Feb;27 (2):102-10
  • Massaia M, Borrione P, Attisano C, Barral P, Beggiato E, Montacchini L, Bianchi A, Boccadoro M, Pileri A. Dysregulated Fas and Bcl-2 expression leading to enhanced apoptosis in T cells of multiple myeloma patients. Blood. 1995 Jun 15;85 (12):3679-87
  • Mor F, Cohen IR. IL-2 rescues antigen-specific T cells from radiation or dexamethasone-induced apoptosis. Correlation with induction of Bcl-2. J Immunol. 1996 Jan 15;156 (2):515-22
  • Park JR, Hockenbery DM. BCL-2, a novel regulator of apoptosis. J Cell Biochem. 1996 Jan;60 (1):12-7
  • Reed JC, Miyashita T, Takayama S, Wang HG, Sato T, Krajewski S, Aime-Sempe C, Bodrug S, Kitada S, Hanada M. BCL-2 family proteins: regulators of cell death involved in the pathogenesis of cancer and resistance to therapy. J Cell Biochem. 1996 Jan;60 (1):23-32
  • Sarbia M, Bittinger F, Porschen R, Verreet P, Dutkowski P, Willers R, Gabbert HE. bcl-2 expression and prognosis in squamous-cell carcinomas of the esophagus. Int J Cancer. 1996 Aug 22;69 (4):324-8
  • Sasatomi E, Tokunaga O, Miyazaki K. Spontaneous apoptosis in gallbladder carcinoma. Relationships with clinicopathologic factors, expression of E-cadherin, bcl-2 protooncogene, and p53 oncosuppressor gene. Cancer. 1996 Nov 15;78 (10):2101-10
Related Products Docs